Compare Freeport-McMoRan Inc (FCX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs TransMedics Group Inc — how do they compare? Freeport-McMoRan Inc trades at $73.09 (market cap $102.16B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Freeport-McMoRan Inc is far larger — about 37.3× TransMedics Group Inc's market cap, and Freeport-McMoRan Inc pays a 0.84% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and TransMedics Group Inc for 24 Days on average.
| FCX | TMDX | |
|---|---|---|
Market Cap | $102.16B | $2.74B |
Volume | 9,047,971 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $150.42 |
52-Week Low | $38.65 | $61.99 |
Typical Hold Time | 69 Days | 24 Days |
Enterprise Value | $108.44B | $3.13B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.87, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $73.27. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $25.92 billion, with net income of $2.20 billion and a net margin of 11.38%. Recent news highlights strong copper demand driven by AI and data center growth, positioning FCX to benefit from favorable market trends.
The outlook for FCX is positive, supported by robust copper demand and expansion projects, but risks include rising production costs and potential regulatory investigations. Analyst sentiment is predominantly bullish, with 61% recommending buy. The stock offers growth potential from commodity tailwinds, though investors should monitor cost pressures and execution of growth initiatives.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
